Amgen
407,27 $Variazione rispetto alla chiusura precedente: −3,38%Variazione assoluta: −14,24 $
Ultime notizie
Titoli nella lingua originale della fonte.
- Amgen (AMGN) Stock Dips While Market Gains: Key Facts (si apre in una nuova scheda)
- Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know (si apre in una nuova scheda)
- 2 Profitable Stocks with Exciting Potential and 1 We Find Risky (si apre in una nuova scheda)
- Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update? (si apre in una nuova scheda)
- Amgen Research Offers Clue to Weight-Loss Drug Paradox (si apre in una nuova scheda)
- Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial (si apre in una nuova scheda)
- Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody (si apre in una nuova scheda)
- Amgen Inc. stock outperforms competitors on strong trading day (si apre in una nuova scheda)
- Is Eli Lilly Stock a Good Fit For Your Portfolio Risk? (si apre in una nuova scheda)
- BMS’s Opdivo patent suit against Amgen adds to eventful 2026 for biosimilar spats (si apre in una nuova scheda)
- Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree? (si apre in una nuova scheda)
- Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead (si apre in una nuova scheda)
- Amgen-Produced Systemic Treatment for Sjogrens Disease Yields Positive Results (si apre in una nuova scheda)
- Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth? (si apre in una nuova scheda)
- Amgen (AMGN), What Is Behind The Fresh Attention? (si apre in una nuova scheda)
- Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk? (si apre in una nuova scheda)
- Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept (si apre in una nuova scheda)
- Amgen Stock Forecast: Sjögren’s Trial Success Tests AMGN’s Pipeline Outlook (si apre in una nuova scheda)
- Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus (si apre in una nuova scheda)
- Why Amgen’s Pipeline Just Got More Interesting (si apre in una nuova scheda)
- Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back (si apre in una nuova scheda)
- Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. (si apre in una nuova scheda)
- 2 Healthcare Stocks That Just Delivered Great News for Investors (si apre in una nuova scheda)
- How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story (si apre in una nuova scheda)
- Amgen’s Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal (si apre in una nuova scheda)
- Amgen (AMGN) Rises Higher Than Market: Key Facts (si apre in una nuova scheda)
- Is LLY Stock Cheaper Than It Looks? (si apre in una nuova scheda)
- Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know (si apre in una nuova scheda)
- The Peptide Boom That Isn’t About Your Muscles (si apre in una nuova scheda)
- How Investors Are Reacting To Veeva Systems (VEEV) Expanding Agentic AI And Winning New Pharma Clients (si apre in una nuova scheda)